Mirae Asset Global Investments Co. Ltd. Acquires 2,464 Shares of Sanofi (NASDAQ:SNY)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Sanofi (NASDAQ:SNY) by 5.6% during the fourth quarter, Holdings Channel reports. The firm owned 46,350 shares of the company’s stock after purchasing an additional 2,464 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Sanofi were worth $2,305,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SNY. Arrowstreet Capital Limited Partnership increased its position in Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after buying an additional 2,468,271 shares during the last quarter. Morgan Stanley boosted its stake in shares of Sanofi by 19.3% during the 4th quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after acquiring an additional 1,251,199 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Sanofi during the 1st quarter valued at about $41,800,000. Envestnet Asset Management Inc. raised its stake in shares of Sanofi by 29.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after acquiring an additional 651,756 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Sanofi by 24.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,643,615 shares of the company’s stock worth $132,260,000 after purchasing an additional 515,245 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SNY. Morgan Stanley initiated coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $55.00.

Sanofi Trading Down 1.6 %

Shares of SNY stock opened at $45.39 on Friday. The firm has a market capitalization of $114.82 billion, a P/E ratio of 19.23, a price-to-earnings-growth ratio of 1.71 and a beta of 0.61. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82. The firm’s fifty day simple moving average is $47.52 and its 200 day simple moving average is $48.67. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, sell-side analysts predict that Sanofi will post 4.16 EPS for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.